Paul G. Allen Family Foundation awards grant for TB vaccine

The Infectious Disease Research Institute was recently awarded a $300,000 grant by the Paul G. Allen Family Foundation to begin clinical trials of a new tuberculosis vaccine.

The two year grant will allow IDRI to commence a Phase 1 clinical trial of a TB vaccine currently known as ID93/GLA-SE. The trial, expected to begin in early 2012, will test the safety and immunogenicity of the vaccine in healthy adult volunteers.

"We are thrilled to be supporting IDRI, a Seattle based not-profit organization focused on addressing infectious diseases, in its effort to develop a vaccine to fight tuberculosis," Susan M. Coliton, the vice president of The Paul G. Allen Family Foundation, said. "This new vaccine could be the solution for the world-wide TB pandemic affecting millions of people.

Preclinical modeling has shown that IDRI’s ID93/GLA-SE vaccine has the potential to deliver substantial protection against the TB microbe, Mycobacterium tuberculosis, both with and without boosting the current BCG vaccine.

IDRI’s vaccine candidate is made up of a fusion protein of antigens and a synthetic antigen formulation. When combined, the two trigger T-cells to induce immunity and protect the body from TB.

"We are extremely thankful for The Paul G. Allen Family Foundation's vision and support in providing critical funding needed to support a clinical trial, which is the critical next phase in the further development of this promising new TB vaccine," Dr. Steven G. Reed, IDRI’s founder and president, said.